Skip to main content

Evidence-Based Decision for Pharmacological Management of Alcoholic Liver Disease and Alcohol Dependence

  • Chapter
  • First Online:
  • 2383 Accesses

Abstract

Alcoholism is a major public health problem, and alcoholic liver disease (ALD) with its complications is still one of the most frequent causes of death in the Western countries. The feasibility of pharmacological treatment in alcoholism has been demonstrated by four currently approved medications, the aldehyde dehydrogenase blocker disulfiram, the gamma-hydroxybutyric acid (GHB), the opioid antagonist naltrexone (NTX), and the glutamate antagonist acamprosate (ACM). In addition, 5HT3 antagonist ondansetron, the GABAB agonist baclofen, and the anticonvulsant topiramate have shown promising results. Moreover, among the other molecules that have already been tested, pentoxifylline (PTX), in a double-blind randomized controlled trial, induce a survival benefit especially in patients with early hepatorenal syndrome, but more trials are needed. Progress in understanding the pathogenesis of AH is leading to new therapies directed to specific mechanism involved in the development of liver injury, such as anti-TNF-a therapy. Pilot studies on the use of the antitumor necrosis factor (TNF) drugs, such as infliximab, in the treatment of alcoholic steato-hepatitis (ASH) have been performed, but the use of this kind of an agent already debuted for the increase of frequency of severe infections in treated group. The therapy of patients with alcohol-related cirrhosis is mainly symptomatic and no therapies are currently available except orthotopic liver transplantation for end-stage liver disease. Independent of the stage of alcohol dependence and ALD, abstinence from alcohol is the cornerstone of management.

Keywords

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, log in via an institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Addolorato G, Leggio L, Ferrulli A, Caputo F, Gasbarrini A (2009) The therapeutic potential of gamma-hydroxybutyric acid for alcohol dependence: balancing the risks and benefits. A focus on clinical data. Expert Opin Investig Drugs 18:675–686

    Article  PubMed  CAS  Google Scholar 

  2. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, Abenavoli L, D’Angelo C, Caputo F, Zambon A, Haber PS, Gasbarrini G (2007) Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 370:1915–1922

    Article  PubMed  CAS  Google Scholar 

  3. Akriviadis E, Botla R, Briggs W et al (2000) Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo controlled trial. Gastroenterology 119:1637–1648

    Article  PubMed  CAS  Google Scholar 

  4. Alexander JF, Lichner MW, Galambos JT (1971) Natural history of alcoholic hepatitis. The long-term prognosis. Am J Gastroenterol 56:515–525

    PubMed  CAS  Google Scholar 

  5. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A, COMBINE Study Research Group (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003–2017

    Article  PubMed  CAS  Google Scholar 

  6. Becker Deis U, Soresen TI et al (1996) Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 23:1025–1029

    Article  Google Scholar 

  7. Bellamy CO, DiMartini AM, Ruppert K et al (2001) Liver transplantation for alcoholic cirrhosis: long term follow-up and impact of disease recurrence. Transplantation 72:619–626

    Article  PubMed  CAS  Google Scholar 

  8. Boetticher NC, Peine CJ, Kwo P et al (2008) A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135:1953–1960

    Article  PubMed  CAS  Google Scholar 

  9. Cabrè E, Gonzalez Huix F, Abad-Lacruz A et al (1990) Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 98:715–720

    PubMed  Google Scholar 

  10. Cabrè E, Rodriguez Iglesias P, Caballeria J et al (2000) On behalf of the spanish group for the Study of Alcoholic Hepatitis. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 32:36–42

    Article  PubMed  Google Scholar 

  11. Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, Del Re A, Comaschi C, Andreone P, Trevisani F, Bernardi M (2007) Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study. Eur Neuropsychopharmacol 17:781–789

    Article  PubMed  CAS  Google Scholar 

  12. Cohen SM, Ahn J (2009) Diagnosis and Management of Alcoholic Hepatitis. Aliment Pharmacol Ther 30(1):3–13

    Article  PubMed  CAS  Google Scholar 

  13. De BK, Gangopadhyay S, Dutta D et al (2009) Pentoxifylline versus prednisolone for severe alcoholic hepatitis: a randomized controlled trial. World J Gastroenterol 15:1613–1619

    Article  PubMed  CAS  Google Scholar 

  14. Dew MA, DiMartini AF, Steel J, De Vito Dabbs A, Myaskovsky L, Unruh M, Greenhouse J (2008) Meta-analysis of risk for relapse to substance use after trans plantation of the liver or other solid organs. Liver Transpl 14(2):159–172

    Article  PubMed  Google Scholar 

  15. DiMartini A, Day N, Dew MA et al (2006) Alcohol consumption patterns and predictors of use following liver transplantation for alcoholic liver disease. Liver Transpl 12:813–820

    Article  PubMed  Google Scholar 

  16. Forrest EH, Evans CD, Stewart S et al (2005) Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 54:1174–1179

    Article  PubMed  CAS  Google Scholar 

  17. Foster PF, Fabrega F, Karademir S et al (1997) Prediction of abstinence from ethanol in alcoholic recipients following liver transplantation. Hepatology 25:1469–1477

    Article  PubMed  CAS  Google Scholar 

  18. Gedaly R, McHugh PP, Johnston TD, Jeon H, Koch A, Clifford TM, Ranjan D (2008) Predictors of relapse to alcohol and illicit drugs after liver transplantation for alcoholic liver disease. Transplantation 86(8):1090–1095

    Article  PubMed  Google Scholar 

  19. Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O’Malley SS, Swift RM, Topiramate for Alcoholism Advisory Board, Topiramate for Alcoholism Study Group (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651

    Article  PubMed  CAS  Google Scholar 

  20. Kamath PS, Kim WR (2007) Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology 45:797–805

    Article  PubMed  Google Scholar 

  21. Kang YJ, Zhou Z (2005) Zinc prevention and treatment of alcoholic liver disease. Mol Aspects Med 26:391–404

    Article  PubMed  CAS  Google Scholar 

  22. Kershenobich D, Vargas F, Garcia-Tsao G et al (1988) Colchicine in the treatment of cirrhosis of the liver. N Eng J Med 318:1709–1713

    Article  CAS  Google Scholar 

  23. Kotlyar DS, Burke A, Campbell MS, Weinrieb RM (2008) A critical review of candidacy for orthotopic liver trans plantation in alcoholic liver disease. Am J Gastroenterol 103(3):734–743

    Article  PubMed  Google Scholar 

  24. Laaksonen E, Koski-Jännes A, Salaspuro M, Ahtinen H, Alho H (2008) A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence. Alcohol Alcohol 43:53–61

    Article  PubMed  CAS  Google Scholar 

  25. Lebrec D, Thabut D, Oberti F et al (2007) Pentoxifylline for the treatment of patients with advanced cirrhosis. A randomized, placebo-controlled, double-blind trial (Abstract). Hepatology 46(Suppl 1):249A

    Google Scholar 

  26. Lieber CS, Weiss DG, Groszman R, et al, The veterans Affairs Cooperative Study 391 Group. II (2003) Veterans Affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res 27:1765–1772

    Article  PubMed  CAS  Google Scholar 

  27. Louvet A, Diaz E, Dharancy S et al (2008) Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 48:465–470

    Article  PubMed  CAS  Google Scholar 

  28. Maddrey WC, Boinott JK, Bedine MS et al (1978) Corticosteroid therapy of alcoholic hepatitis. Gas troen terology 75:193–199

    PubMed  CAS  Google Scholar 

  29. Mandayam S, Jamal MM, Morgan TR (2004) Epidemiology of alcoholic liver disease. Semin Liver Dis 24:217–232

    Article  PubMed  Google Scholar 

  30. Mathurin P, Abdelnour M, Ramond MJ et al (2003) Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38:1363–1369

    PubMed  CAS  Google Scholar 

  31. Mathurin P, Mendenhall CL, Carithers RL Jr et al (2002) Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36:480–487

    Article  PubMed  CAS  Google Scholar 

  32. McCullogh AJ, O’Connor JF (1998) Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol 93:2022–2036

    Article  Google Scholar 

  33. McSween RNM, Burt AD (1986) Histological spectrum of alcoholic liver disease. Semin Liver Dis 3:221–232

    Article  Google Scholar 

  34. Mendenhall CL, Anderson S, Garcia-Pont P et al (1984) Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Eng J Med 311:1464–1470

    Article  CAS  Google Scholar 

  35. Mendenhall CL, Tosch T, Weesner RE et al (1986) VA cooperative study on alcoholic hepatitis. II. Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 43:213–218

    PubMed  CAS  Google Scholar 

  36. Murray KF, Carithers RL Jr, AASLD (2005) AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology 41(6):1407–1432

    Article  PubMed  Google Scholar 

  37. Naveau S, Chollet-Martin S, Dharancy S et al (2004) A double blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39:1390–1397

    Article  PubMed  CAS  Google Scholar 

  38. Neuberger J, Schulz KH, Day C et al (2002) Transplantation for alcoholic liver disease. J Hepatol 36:130–137

    Article  PubMed  Google Scholar 

  39. Ntais C, Pakos E, Kyzas P, Ioannidis JP (2005) Ben zodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 20(3):CD005063

    Google Scholar 

  40. Orrego H, Blake JE, Blendis LM et al (1987) Long-term treatment of alcoholic liver disease with propylthiouracil. N Eng J Med 317:1421–1427

    Article  CAS  Google Scholar 

  41. Pfitzmann R, Schwenzer J, Rayes N et al (2007) Long-term survival and predictors of relapse after orthotopic liver transplantation for alcoholic liver disease. Liver Transpl 13:197–205

    Article  PubMed  Google Scholar 

  42. Polycarpou A, Papanikolaou P, Ioannidis JP, Contopoulos-Ioannidis DG (2005) Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 20(3):CD005064

    Google Scholar 

  43. Rambaldi A, Gluud C (2001) Meta-analysis of propylthiouracil for alcoholic liver disease-a Cochrane Hepato-Biliary Group review. Liver 21:398–404

    Article  PubMed  CAS  Google Scholar 

  44. Rambaldi A, Gluud C (2001) Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 3:CD002148

    PubMed  Google Scholar 

  45. Rambaldi A, Gluud C (2006) S-adenosyl-L-methionine for alcoholic liver disease. Cochrane Database Syst Rev 19(2):CD002235

    Google Scholar 

  46. Rambaldi A, Gluud C (2006) Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev (Online) 4:CD003045

    Google Scholar 

  47. Rambaldi A, Saconato HH, Christensen E et al (2008) Systematic review: glucocorticosteroids for alcoholic hepatitis-a Cochrane Hepatobiliary Group systematic review with meta-analyses and trial sequential analyses of randomized clinical trials. Aliment Pharmacol Ther 27:1167–1178

    Article  PubMed  CAS  Google Scholar 

  48. Schuckit MA (2009) Alcohol use disorders. Lancet 373:492–501

    Article  PubMed  Google Scholar 

  49. Sidhu S, Singla M, Bhatia K (2006) Pentoxifylline reduces disease severity and prevents renal impairment in severe acute alcoholic hepatitis: a double blind, placebo controlled trial (Abstract). Hepatology 44(Suppl 1):373A

    Google Scholar 

  50. Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 25(1):CD001867

    Google Scholar 

  51. Stewart S, Prince M, Bassendine M et al (2007) A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis. J Hepatol 47:277–283

    Article  PubMed  CAS  Google Scholar 

  52. Sticel F, Hoen B, Schuppan D et al (2003) Nutritional therapy in alcoholic liver disease. Aliment Pharmacol Ther 18:357–373

    Article  Google Scholar 

  53. Teli MR, Day CP, Burt AD et al (1995) Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 346:987–990

    Article  PubMed  CAS  Google Scholar 

  54. Tilg H, Jalan R, Kaser A et al (2003) Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38:419–425

    Article  PubMed  CAS  Google Scholar 

  55. Tome S, Lucey MR (2004) Review article: current management of alcoholic liver disease. Aliment Pharmacol Ther 19:707–714

    Article  PubMed  CAS  Google Scholar 

  56. Trinchet JC, Balkau B, Poupon RE et al (1992) Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial. Hepatology 15:76–81

    Article  PubMed  CAS  Google Scholar 

  57. Veldt BJ, Laine F, Guillygomarc’h A et al (2002) Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J Hepatol 36:93–98

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Francesco Giuseppe Foschi .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Foschi, F.G. et al. (2010). Evidence-Based Decision for Pharmacological Management of Alcoholic Liver Disease and Alcohol Dependence. In: Chiappelli, F. (eds) Evidence-Based Practice: Toward Optimizing Clinical Outcomes. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-05025-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-05025-1_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-05024-4

  • Online ISBN: 978-3-642-05025-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics